Towards safer risperidone prescribing in Alzheimer's disease

Suzanne Reeves, Julie Bertrand, Hiroyuki Uchida, Kazunari Yoshida, Yohei Otani, Mikail Ozer, Kathy Y. Liu, Elvira Bramon, Robert Bies, Bruce G. Pollock, Robert Howard

Research output: Contribution to journalArticlepeer-review

Abstract

Background In the treatment of psychosis, agitation and aggression in Alzheimer's disease, guidelines emphasise the need to 'use the lowest possible dose' of antipsychotic drugs, but provide no information on optimal dosing. Aims This analysis investigated the pharmacokinetic profiles of risperidone and 9-hydroxy (OH)-risperidone, and how these related to treatment-emergent extrapyramidal side-effects (EPS), using data from The Clinical Antipsychotic Trials of Intervention Effectiveness in Alzheimer's Disease study (Clinicaltrials.gov identifier: NCT00015548). Method A statistical model, which described the concentration-time course of risperidone and 9-OH-risperidone, was used to predict peak, trough and average concentrations of risperidone, 9-OH-risperidone and 'active moiety' (combined concentrations) (n = 108 participants). Logistic regression was used to investigate the associations of pharmacokinetic biomarkers with EPS. Model-based predictions were used to simulate the dose adjustments needed to avoid EPS. Results The model showed an age-related reduction in risperidone clearance (P < 0.0001), reduced renal elimination of 9-OH-risperidone (elimination half-life 27 h), and slower active moiety clearance in 22% of patients, (concentration-to-dose ratio: 20.2 (s.d. = 7.2) v. 7.6 (s.d. = 4.9) ng/mL per mg/day, Mann-Whitney U-test, P < 0.0001). Higher trough 9-OH-risperidone and active moiety concentrations (P < 0.0001) and lower Mini-Mental State Examination (MMSE) scores (P < 0.0001), were associated with EPS. Model-based predictions suggest the optimum dose ranged from 0.25 mg/day (85 years, MMSE of 5), to 1 mg/day (75 years, MMSE of 15), with alternate day dosing required for those with slower drug clearance. Conclusions Our findings argue for age- and MMSE-related dose adjustments and suggest that a single measure of the concentration-to-dose ratio could be used to identify those with slower drug clearance.

Original languageEnglish
Pages (from-to)268-275
Number of pages8
JournalBritish Journal of Psychiatry
Volume218
Issue number5
DOIs
Publication statusPublished - 2021 May
Externally publishedYes

Keywords

  • Antipsychotics
  • drug interactions and side-effects
  • outcome studies
  • pharmaceutical drug trial
  • randomised controlled trial

ASJC Scopus subject areas

  • Psychiatry and Mental health

Fingerprint

Dive into the research topics of 'Towards safer risperidone prescribing in Alzheimer's disease'. Together they form a unique fingerprint.

Cite this